All News
Pregnant women with ARDs esp. SLE nephritis and primary APS have significantly higher risks for acute CVEs compared to those without these conditions. 25-30% of CVEs occurred during the postpartum period, Dhital R Abst#0722 #ACR23 #ACRBest @RheumNow https://t.co/m9FjsAu64N https://t.co/1dyTzgH97A
Dr. Antoni Chan ( View Tweet)
Reduced-dose GC regimen in severe GPA or MPS (creatinine >300 umol/L, RTX as induction) associated with increased risk of death, ESKD, progression before remission requiring treatment modification or relapse, Nagle S Abst#0725 #ACR23 #ACRBest @RheumNow https://t.co/ZVZYRnSy3n
Dr. Antoni Chan ( View Tweet)
What a talk. @DrPujaMehta1 on the big stage, with a truly inspirational talk in the #ACR23 Daltroy Lecture.
If you have any thoughts at all on DEI, or just are curious, you need to watch this.
I need to listen to it again, but two initial key points for me:
@RheumNow https://t.co/G4lngvpdS7
David Liew drdavidliew ( View Tweet)
Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo
Richard Conway ( View Tweet)
Two initial points for me:
1. Challenge how we see all this, lot of current thinking misses the mark
2. Action, not just acknowledgement, but needs to be thoughtful about what it achieves, not just reactive
I’m not doing it justice. Listen to the whole thing!
#ACR23 @RheumNow https://t.co/ydb8COnqtA
David Liew drdavidliew ( View Tweet)
@Yuz6Yusof @RheumNow @EBRheum Look at all these @RheumNow people here in person #ACR23! https://t.co/aoxirYrxIU
David Liew drdavidliew ( View Tweet)
Finger fold index (FFI) calculated by deep neural network model reliable for metrical analysis and detection of swelling in RA with 91% accuracy. Mean FFI significantly higher in RA vs healthy controls PIP joints @marcblanchard23 Abst#0402 #ACR23 @RheumNow https://t.co/jmPvwzf2m8 https://t.co/DOZoV0xSsd
Dr. Antoni Chan ( View Tweet)
Great meeting @Janetbirdope at @RheumNow stand and being in the faculty together reporting at #ACR23, she is a great teacher with lots of great content on her site so do follow her https://t.co/zK9jihqjgy
Dr. Antoni Chan ( View Tweet)
Urinary biomarkers precede loss of kidney fxn in LN by @andreafava
#Ab0850 @RheumNow #ACR23
73 pts w LN. 44% devel GFR loss
Elevation of urinary biomark of histo activity at 6, 12 mo predict GFR loss at 3 yrs - esp IL-16, >> proteinuria
Combo biomark 12 mo: AUC 0.95
#ACRBest https://t.co/M7sfpCm7Kz
Eric Dein ( View Tweet)
Access all areas - behind the scene 🎬 @RheumNow with fantastic colleagues and crews 🤩🙌🏻🫶🏼 https://t.co/ZHwcPZt7kh
Md Yuzaiful Md Yusof ( View Tweet)
Shout out to @RheumNow, @Janetbirdope, @drdavidliew, and @EBRheum for amazing coverage of #ACR23! I am sad to be missing it in person, but have my finger on the pulse of Rheumatology this year via these savvy experts. Thank you!
Dr. Jason J Lee (이주헌) ( View Tweet)
AI predict ANA specific Abs? @AliDuarteMD
Ab#0852 #ACR23 @RheumNow
410K pts test for ANA HEp-2 IFA (136K pos, 47K specific autoAb)
AI prediction models >0.80 AUC exc for RNP, Scl70
More predictive than traidtional staining patterns (p<0.001), except centromere (similar) https://t.co/4ZvP79rEdl
Eric Dein ( View Tweet)
TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety.
“This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann
#ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ
David Liew drdavidliew ( View Tweet)
More on TLL-018
How?
A: Everyone surprised. But maybe dual mech benefits re: pain via IFN
Where’s the multinational RCT in RA?
A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent.
#ACR23 @RheumNow
David Liew drdavidliew ( View Tweet)
What if we deliver TNFi to the wrong place?
Delivery of ETA to peripheral lymphatics instead of subcut through a wearable device in 10pts showed:
1- is Safe
2-Reduces DAS28 (but more TJC than SJC)
To be confirmed in larger and controlled study!
@RheumNow #ACR23 ABST0838 https://t.co/IUPpFwjjbj
Aurelie Najm ( View Tweet)
Colchicine - what a fascinating medicine.
From a rheum point of view, interesting to see it play out for secondary prevention coronary artery disease, lot of patients. Great we can share our collective clinical confidence with it with cardiology
#ACR23 @US_FDA session @RheumNow https://t.co/Q7zLtyby8l
David Liew drdavidliew ( View Tweet)
Results of this study by Dr Fava show that most urinary BMs of histological activity were⬆️at 6 & 12mos in pts who lost GFR at 3yrs.
☝️Some LN pts still develop renal damage despite clinical response. Is there a role for BMs in monitoring tx?
#ACR23 ABST0850 @RheumNow #ACRbest https://t.co/H5G6LJ22lw
sheila ( View Tweet)
#ACR23 family memories! @KDAO2011 @RheumNow https://t.co/SFa12nL4vR
Dr. Rachel Tate ( View Tweet)
Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @RheumNow https://t.co/UHjti200yh https://t.co/tkSlLMIl7X
Richard Conway ( View Tweet)